369 related articles for article (PubMed ID: 31477842)
1. SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K/AKT/SOX2 axis and beyond.
Schaefer T; Lengerke C
Oncogene; 2020 Jan; 39(2):278-292. PubMed ID: 31477842
[TBL] [Abstract][Full Text] [Related]
2. SOX2 and p53 Expression Control Converges in PI3K/AKT Signaling with Versatile Implications for Stemness and Cancer.
Schaefer T; Steiner R; Lengerke C
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664542
[TBL] [Abstract][Full Text] [Related]
3. CircABCC3 knockdown inhibits glioblastoma cell malignancy by regulating miR-770-5p/SOX2 axis through PI3K/AKT signaling pathway.
Zhang H; Xu W
Brain Res; 2021 Aug; 1764():147465. PubMed ID: 33811842
[TBL] [Abstract][Full Text] [Related]
4. SOX2 in development and cancer biology.
Novak D; Hüser L; Elton JJ; Umansky V; Altevogt P; Utikal J
Semin Cancer Biol; 2020 Dec; 67(Pt 1):74-82. PubMed ID: 31412296
[TBL] [Abstract][Full Text] [Related]
5. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.
Corominas-Faja B; Cufí S; Oliveras-Ferraros C; Cuyàs E; López-Bonet E; Lupu R; Alarcón T; Vellon L; Iglesias JM; Leis O; Martín ÁG; Vazquez-Martin A; Menendez JA
Cell Cycle; 2013 Sep; 12(18):3109-24. PubMed ID: 23974095
[TBL] [Abstract][Full Text] [Related]
6. Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells.
Vazquez-Martin A; Cufí S; López-Bonet E; Corominas-Faja B; Cuyàs E; Vellon L; Iglesias JM; Leis O; Martín AG; Menendez JA
Cell Cycle; 2013 Nov; 12(22):3471-7. PubMed ID: 24107627
[TBL] [Abstract][Full Text] [Related]
7. Linking Pluripotency Reprogramming and Cancer.
Iglesias JM; Gumuzio J; Martin AG
Stem Cells Transl Med; 2017 Feb; 6(2):335-339. PubMed ID: 28191771
[TBL] [Abstract][Full Text] [Related]
8. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
10. SOX2/SALL4 stemness axis modulates Notch signaling genes to maintain self-renewal capacity of esophageal squamous cell carcinoma.
Forghanifard MM; Kasebi P; Abbaszadegan MR
Mol Cell Biochem; 2021 Feb; 476(2):921-929. PubMed ID: 33098486
[TBL] [Abstract][Full Text] [Related]
11. Regulation of colorectal carcinoma stemness, growth, and metastasis by an miR-200c-Sox2-negative feedback loop mechanism.
Lu YX; Yuan L; Xue XL; Zhou M; Liu Y; Zhang C; Li JP; Zheng L; Hong M; Li XN
Clin Cancer Res; 2014 May; 20(10):2631-42. PubMed ID: 24658157
[TBL] [Abstract][Full Text] [Related]
12. SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway.
Yang N; Hui L; Wang Y; Yang H; Jiang X
Oncol Rep; 2014 Jun; 31(6):2651-9. PubMed ID: 24700142
[TBL] [Abstract][Full Text] [Related]
13. AKT drives SOX2 overexpression and cancer cell stemness in esophageal cancer by protecting SOX2 from UBR5-mediated degradation.
Wang Z; Kang L; Zhang H; Huang Y; Fang L; Li M; Brown PJ; Arrowsmith CH; Li J; Wong J
Oncogene; 2019 Jun; 38(26):5250-5264. PubMed ID: 30894683
[TBL] [Abstract][Full Text] [Related]
14. SETD8 promotes stemness characteristics and is a potential prognostic biomarker of gastric adenocarcinoma.
Piao L; Che N; Li H; Li M; Feng Y; Liu X; Kim S; Jin Y; Xuan Y
Exp Mol Pathol; 2020 Dec; 117():104560. PubMed ID: 33127342
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of Sox2 cooperates in reprogramming to pluripotent stem cells.
Jeong CH; Cho YY; Kim MO; Kim SH; Cho EJ; Lee SY; Jeon YJ; Lee KY; Yao K; Keum YS; Bode AM; Dong Z
Stem Cells; 2010 Dec; 28(12):2141-50. PubMed ID: 20945330
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
[TBL] [Abstract][Full Text] [Related]
17.
Chuang HM; Huang MH; Chen YS; Harn HJ
Cell Transplant; 2020; 29():963689720907565. PubMed ID: 32233795
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel promotes cell apoptosis and decreases SOX2 expression in CD133‑expressing hepatocellular carcinoma stem cells by suppressing the PI3K/AKT signaling pathway.
Zhang X; Shao J; Li X; Cui L; Tan Z
Oncol Rep; 2019 Feb; 41(2):1067-1074. PubMed ID: 30483804
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
20. Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1.
Schaefer T; Ramadoss A; Leu S; Tintignac L; Tostado C; Bink A; Schürch C; Müller J; Schärer J; Moffa G; Demougin P; Moes S; Stippich C; Falbo S; Neddersen H; Bucher H; Frank S; Jenö P; Lengerke C; Ritz MF; Mariani L; Boulay JL
Brain Pathol; 2019 May; 29(3):336-350. PubMed ID: 30403311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
